Preliminary reports indicate that sirolimus-eluting stents reduce the risk of restenosis after percutaneous infrapopliteal artery revascularization. We conducted a prospective, randomized, multi-centre, double-blind trial comparing a polymer-free sirolimus-eluting stent with a placebo-coated bare-metal stent in patients with either intermittent claudication or critical limb ischaemia who had a de-novo lesion in an infrapopliteal artery.
Introduction
Peripheral artery disease with intermittent claudication (IC) or critical limb ischaemia (CLI) represents a major challenge for all healthcare specialists involved in the treatment of atherosclerotic disease. Greater life expectancy and the increasing prevalence of diabetes mellitus in the developed countries lead to a progressively rising number of patients with CLI and IC due to infrapopliteal artery (IPA) disease. 1 Moreover, there is increasing evidence that patency rates after femoro-popliteal artery interventions are positively affected by the number of patent IPA in patients with IC. 2 -5 Today the endovascular approach has become the first-line strategy for the treatment of IPA lesions. Although advances have been made in innovative technologies such as lesion modification and atheroablation, 6 balloon angioplasty (PTA) continues to be the mainstay of endovascular therapy for the treatment of infrapopliteal disease. Stent placement is currently reserved for suboptimal results after PTA such as significant recoil, flow-limiting dissection, or residual stenosis. 7 However, PTA and bare-metal stents (BMS) have failed to demonstrate durability, restenosis following BMS placement continue to exceed 50% after 1 year. 1, 8 The use of sirolimus-eluting stents (SES) with their proven efficacy in the treatment of coronary artery disease could be of major advance in the treatment of patients with infrapopliteal lesions. The rationale of this double-blinded randomized study was to prove the concept of using SES to improve primary patency rates after interventional therapy of focal lesions of IPA.
Methods

Study design
The study was a prospective, randomized, double-blind trial performed at four medical centres. It was approved by the ethics committee at each participating institution, and all patients gave written informed consent. Patients were eligible for the study if they were at least 21 years old, were not pregnant, and suffered from peripheral artery disease with a Rutherford-Becker class (RC) of 3 to 5. Patients with lifestyle-limiting claudication RC 2 could also be included after successful intervention of TASC A (single stenosis less than 3 cm of the superficial femoral artery or popliteal artery) femoro-popliteal lesions to improve run-off status. Angiographic eligibility criteria were the presence of a single primary target lesion in a native IPA that was 2.5 -3.5 mm in diameter and that did not exceed 45 mm in length to assure complete lesion coverage by the treatment with a maximum of two stents with a stent length of 25 mm; diameter stenosis of at least over 70%, as estimated by duplex-ultrasound (DU) and visually on angiography. Major exclusion criteria were a visible thrombus within target lesion, known systemic coagulopathy, Buerger's disease, acute limb ischaemia, and life expectancy less than 1 year, or an intolerance of aspirin, clopidogrel, and heparin.
Study procedures
We allocated patients to the two treatment groups using a computergenerated random sequence, set in blocks for each participating centre. Patients were randomly assigned to the groups in a 1:1 ratio. After successful crossing of the target lesion with the guide wire, patients were randomly assigned to receive a BMS or a polymer-free SES (Yukon TM , Translumina w , Hechingen, Germany). The BMS was coated with ethanol (placebo) and the polymer-free SES was coated with a 2% sirolimus-containing solution.
Predilatation of the target lesion was left to discretion of the physician. The SES and the BMS were identical in appearance; there was no difference in packing or labelling of the stents. Physicians and patients were unaware of the treatment-group assignment. A successful procedure was defined as the successful implantation of the study device, with stenosis of less than 20% of the vessel diameter.
Before and after the index procedure, all patients received oral aspirin (100 mg daily) and oral clopidogrel (a loading dose of 600 mg 24 h before the procedure followed by 75 mg daily for 6 months).
Stent-coating procedure
Both stent types (SES and BMS) were coated in a pharmacy with a stent-coating machine developed by Translumina w (Hechingen, Germany). The stent-coating machine enables a polymer-free-coating process with a sterile coating in a special single-use stent cartridge. The stent surface contains micro-pores to enable the adsorption of organic substances. The sirolimus-coating solution fills the pores completely and creates a layer after evaporation of the solvent. This stent is CE-marked and was already used in several studies relating to stent placement in the coronary artery bed.
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Follow-up
The preinterventional work-up and the follow-up visits after 6 and 12 months included clinical examination, calculation of the ankle brachial index (ABI), and DU (3 -9 MHz linear transducer, IU 22 Philips, Bothell, WA, USA). Angiography was performed in case of any condition limiting DU (e.g. media calcinosis, obesity), or in case of target lesion revascularization (TLR). Redo angioplasty was performed only if restenosis was associated with recurrent symptoms of claudication and/or worsening or increasing skin lesion. All clinical endpoints were adjudicated by an independent clinical-events committee. All physicians including the medical staffs, the research coordinators, and the clinical-events committee were blinded for the treatment-group assignments.
Study endpoints
The main study endpoint was primary patency rate after 1 year, defined as freedom from in-stent-restenosis (luminal narrowing of ,50%) detected with DU or angiography if appropriate. The definition of 50% restenosis was based on a peak systolic velocity ratio (peak systolic velocity within the stent divided by peak systolic velocity at least 1 cm proximal of the stent in a healthy vessel segment) .2.4.
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The presence of a significant restenosis was confirmed by intra-arterial angiography during clinically driven TLR in all cases. Secondary endpoints included primary patency rate after 6 months and secondary patency rate, defined as patency following successful TLR after 12 months. The ABI and the stage of disease according to the RC after 6 and 12 months were examined.
Death, major-and minor amputation, TLR including need for surgical revascularization, and myocardial infarction were defined as major adverse events. All major events were determined cumulatively for 370 days after stent placement.
Statistical analysis
Based on the published data, we assumed a patency rate of 50% with BMS. The study was designed to have a power of 95% to detect an elevation of the patency rate by the SES to 75% with a two-sided P , 0.05. Considering a dropout rate of 30% we obtained a total sample size of 155 patients.
Data for all endpoints were evaluated in the intention-to-treat analysis. Continuous data are expressed as mean + standard deviation (SD). Categorical variables were compared with the use of the two-sided chi-square test and continuous variables were compared with the use of the two-sided Students's t-test. Changes in RC were expressed as median with interquartile range. To control unbalanced data changes in RC and ankle brachial index were modelled using repeated measures analysis. Event-free survival was compared by Kaplan -Meier analysis with the use of the Mantel -Cox log-rank test constructed by SPSS software, version 16.0. A two-sided P value of less than 0.05 was considered to indicate statistical significance. To summarize differences in the primary endpoint between the study groups, we derived hazard ratios with associated 95% confidence intervals (CIs) from the Cox proportional hazards model. To assess the interaction of stent type with stage of disease (CLI or IC) and to adjust for remaining imbalance, we performed Cox regression analyses.
Sirolimus-eluting stents vs. bare-metal stents
Results
Patient characteristics
Between April 2006 and April 2008, 82 patients were randomly assigned to receive the polymer-free SES, and 79 were assigned to receive the BMS. With the exception of a significantly higher body-mass index in the SES group, the two groups were similar with respect to all baseline variables. Overall, 67% of the patients were men; the mean age was 73 + 9 years. Forty-seven percent (n ¼ 75) of the patients suffered from CLI (RC 4 or 5), 53% (n ¼ 86) suffered from IC (RC 2 or 3).
The mean target lesion length was 31 + 9 mm. Thirty-six occlusions were treated ( Table 1) . Thirty (36.6%) patients in the SES group and 25 (31.6%; P ¼ 0.62%) patients in the BMS group had additional femoro-popliteal lesions that were treated prior to randomization.
Acute results
An average of 1.3 (Range 1-3) stents was implanted per target lesion. Due to study stent dislocation in one (1.2%) patient of the SES group and two (2.5%) patients of the BMS group, three stents had to be implanted to cover the target lesion. There was no significant difference between the study groups concerning the number of patent IPA after the index procedure ( Table 2) .
The mean ABI increased significantly from 0.48 + 0.16 at baseline to 0.84 + 0.17 at discharge (P , 0.0001), with no significant difference between the groups ( Table 2 ).
Results at 6 and 12 months
Twenty-five (15.5%) patients died, eight (4.9%) patients were lost during the follow-up period, and three (1.9%) patients could only be contacted by telephone due to care dependency. Sixty-two (76.5%) patients in the SES group and 63 (79.7%) patients in the BMS group completed 1-year follow-up ( Figure 1 ). Due to inappropriate DU or TLR angiography was performed in 55 (44%) patients.
The rates of ≥50% target lesion restenosis after 1 year were 19.4% (n ¼ 12) for the SES group and 44.4% (n ¼ 28) for the BMS group. Hence, the 1-year primary patency rates were 80.6% (n ¼ 50) and 55.6% (n ¼ 35; P ¼ 0.004), and 6-month primary patency rates were 85.9% (n ¼ 55) and 68.7% (n ¼ 46; P ¼ 0.02), respectively. The secondary 1-year patency rates were 91.9% a Plus-minus values are means + SD. There were no significant differences between the treatment groups except for body mass index (P ¼ 0.044). with a hazard ratio for restenosis of 3.2 (95% CI 1.5 to 6.7; P ¼ 0.003) compared with SES after 1 year. The risk of restenosis associated with BMS prevailed after adjustment for diabetes mellitus, smoking status, and body-mass index. The corresponding adjusted hazard ratio was 3.0 (95% CI 1.4 to 6.4; P ¼ 0.005). No significant interaction could be observed between stent type and stage of disease (CLI or IC) regarding the primary endpoint when added to the Cox regression model. The median (interquartile range, IQR) RC decreased from 4 (3 to 5) in the SES group and 3 (3 to 5) in the BMS group (P ¼ 0.40) at baseline to 1 (1 to 3) and 2 (1 to 3; P ¼ 0.37) at 6 months and 2 (0.75 to 3) and 2 (1 to 3; P ¼ 0.01) at 1 year, respectively. Moreover, the median (IQR) change in RC was 22 (23 to 21) in the SES group and 21 (22 to 0; P ¼ 0.12) at 6 months and 22 (23 to 21) and 21 (22 to 0) in the BMS group at 1 year, respectively (P ¼ 0.004, Table 3 ).
The mean ABI increased from 0.49 + 0.15 in the SES group and 0.51 + 0.15 (P ¼ 0.72) in the BMS group at baseline to 0.72 + 0.16 and 0.65 + 0.13 (P ¼ 0.14) after 12 months, respectively.
Adverse events
A total of 51 (31.5%) adverse events occurred, 22 (27.1%) in the SES group, and 29 (36.7%) in the BMS group. In the SES group, 14 patients (17.1%) and 11 patients (13.9%, P ¼ 0.66) in the BMS group died during the follow-up period: eight patients (5%) died because of major cardiac events (myocardial infarction, heart failure). Five patients (3.1%) died as a result of gastrointestinal and pulmonary infections; one patient (0.6%) had lung cancer. In 11 patients (6.8%) the cause of death remained uncertain.
During follow-up TLR was performed in six patients (9.7%) in the SES group and in 11 patients (17.5%) in the BMS group (P ¼ 0.29; Figure 2 ), target limb reintervention (inflow lesion) was performed in eight patients (12.9%) and seven patients (11.1%, P ¼ 0.84), respectively. Due to insufficiently controlled wound infection despite adequate antibiotic treatment, one lower-leg major amputation and one minor toe amputation of the target limb in the SES group (3.2%), and two lower-leg major amputations and two minor toe amputations in the BMS group (6.4%) were documented, respectively. Hence, the limb salvage rate was 98.4% in the Sirolimus-eluting stents vs. bare-metal stents SES group and 96.8% in the BMS group after 12 months (P ¼ 0.61). Three patients in the BMS group suffered myocardial infarction between 6 and 8 months after the index procedure.
The Kaplan -Meier estimates of clinical events free survival for the two groups during follow-up are shown in Figure 3 .
Results at 12 months in patients with CLI at baseline
One-year primary patency rates were 75% (n ¼ 21) for the SES and 56.5% (n ¼ 13; P ¼ 0.23) for the BMS group. Secondary 1-year patency rates were 92.9% (n ¼ 26) and 69.6% (n ¼ 16; P ¼ 0.06), respectively.
The median (IQR) RC decreased from 5 (5) in the SES group and 5 (5; P ¼ 0.22) in the BMS group at baseline to 2 (1 to 3) and 3 (2 to 5; P ¼ 0.07) at 1 year, respectively. The median (IQR) change in RC was 23 (22 to 24) in the SES group and 22 (0 to 23; P ¼ 0.13) at 1 year, respectively. In patients suffering from ulcers at baseline, 42.7% in the SES group vs. 39.2% in the BMS group, a wound healing could be observed in 19 (86.4%) patients and in 14 (66.6%; P ¼ 0.16) patients at 1-year follow-up, respectively.
The mean ABI increased from 0.35 + 0.18 in the SES group and 0.45 + 0.15 in the BMS group (P ¼ 0.33) at baseline to 0.71 + 0.14 and 0.64 + 0.14 (P ¼ 0.23) after 12 months, respectively. No significant differences concerning major adverse events could be observed between the treatment groups ( Table 4) .
Results at 12 months in patients with IC at baseline
One-year primary patency rates were 85.3% (n ¼ 29) in the SES group and 55% (n ¼ 22; P ¼ 0.006) in the BMS group. Secondary 1-year patency rates were 91.2% (n ¼ 31) and 72.5% (n ¼ 29; P ¼ 0.07), respectively.
The median (IQR) RC decreased from 3 (3) in the SES group and 3 (3; P ¼ 0.43) in the BMS group at baseline to 1 (0 to 2) and 2 (1 to 3; P ¼ 0. . ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ ......   .... ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ .... median (IQR) change in RC was 21.5 (23 to 21) in the SES group and 21 (22 to 0; P ¼ 0.01) in the BMS group at 1 year. The mean ABI increased from 0.54 + 0.09 in the SES group and 0.53 + 0.15 in the BMS group (P ¼ 0.79) at baseline to 0.73 + 0.17 and 0.66 + 0.12 (P ¼ 0.23) after 12 months, respectively. No significant differences concerning major adverse events could be observed between the treatment groups ( Table 5) .
Discussion
To our knowledge, this is the first randomized, double-blinded, multi-centre study showing favourable outcomes for SES compared to BMS in infrapopliteal application. PTA or stent placement of IPA is still the subject of some controversy. Although it has become an established treatment for CLI patients, 1,13 -15 interventional therapy of IPA in patients with IC is not yet accepted as a therapy option, despite published data underlining the beneficial clinical effect. 2 -5,16 -19 PTA and stent placement using BMS provide promising acute procedural results in the treatment of IPA but the clinical durability is hampered by restenosis rates of more than 70% with PTA and more than 50% with BMS after 1 year. 8, 17, 20, 21 To assure the double-blinded design a polymer-free sirolimus-eluting stent was used in this trial. Using a porcine coronary model of restenosis, it was found that sirolimus coating is feasible and effectively reduces neointimal proliferation. 22 In a clinical study in which the efficacy of several doses of sirolimus was Sirolimus-eluting stents vs. bare-metal stents assessed, it could be documented that a non-polymer coating with sirolimus is safe and leads to a dose-dependent reduction in restenosis. 23 Similar to the coronary circulation the use of polymer-free SES resulted in significantly higher primary and secondary patency rates after 6 and 12 months. Consistently, the number of clinically driven TLR was nearly half the number with BMS for SES after 1 year. Our results support the assumptions derived from previous studies using SES with polymer coating. 8,19,24 -28 These non-randomized trials enrolled patients with a mean age of 72 years, just over half were diabetic. The mean lesion length in these trials ranged from 8 to 36 mm, the 1-year primary patency rates ranged from 83 to 90%, and the TLR from 6.7 to 9.1% in the SES groups. The present study reveals comparable results in the polymer-free SES group with a 1-year primary patency rate of 80.6% and TLR of 9.7%. Noteworthy, the 1-year primary patency rate and TLR in the BMS group is also comparable with the results for BMS in former studies.
Published non-randomized data demonstrate an improvement in RC from baseline to follow-up in 88-95% of patients after SES placement for the treatment of IPA lesions. 18, 19, 25, 29 In the present trial, 83.9% of patients in the SES group and 61.9% in the BMS group show an improvement in RC 12 months after the index procedure. Hence, corresponding to the technical results, the changes in RC reveal a significant advantage for the SES group compared to the BMS group during follow-up. No significant differences between the study groups concerning mortality and amputation rates were observed. The overall mortality rate of 22.6% in patients with CLI and 9.3% in patients with IC after 1 year reflects the limited life expectancy of this severely diseased patient population. 30, 31 Major and minor amputations occurred only in patients with CLI at baseline. The limb salvage rate in the study cohort is comparable with previous studies with BMS. 17,18,32 -34 In this context one must throw into question the treatment with the more expensive SES to become the standard of care before end of life for individuals with IPA disease. However, including patients with IC and CLI, the study was not designed to prove a significant reduction in amputation rate and TLR rate potentially resulting in a cost benefit for SES treatment of IPA. Moreover, independently to the cost, the significantly better improvement in RC in comparison to the BMS group probably had a positive effect on the quality of life of patients treated with SES. The course of the ABI did not show significant differences between the study groups during follow-up. This might be explained by the low proportion of patients with compressible calf arteries. Hence, the validity of the ABI measurement in this patient cohort is limited.
Primary patency of SES was significantly higher in patients suffering from IC whereas primary patency of SES in patients with CLI was only superior to BMS by trend. No significant interaction was found concerning the stage of disease (CLI or IC) and the primary endpoint (P ¼ 0.39). This subgroup analysis of the primary and secondary endpoints is limited by the small sample size -74 (86.1%) patients with IC and only 51 (68%) patients with CLI at baseline completed the 1-year follow-up examinations. Although statistical significance was not reached, as the study was not powered for these endpoints, the higher primary patency rate, wound-healing rate, and the significantly higher secondary patency rate in CLI patients treated with SES probably have an impact on amputation and limb salvage rates in bigger cohorts and with greater follow-up periods as identified in a recently published studies. 7, 18 Moreover, significant savings secondary to preserving independent living and reducing custodial care should not be underestimated. In addition; for patients with lifestyle-limiting IC these results are of critical importance, supporting findings that treatment of IPA lesions probably has an impact on the occurrence of IC 2 -5 and that once treated, these patients profit from the durability of SES placement in terms of lasting improvement in RC and a nearly quartered TLR rate in comparison with BMS. Angiography is still the gold standard for the diagnosis of IPA disease. However, this method is not free of complications and side effects and mostly gives morphologic but no haemodynamic information about lesions. DU allows haemodynamic evaluation non-invasively and with comparable reliability as angiography, as shown in some studies, as angiography. 10,34 -36 DU identification of proximal IPA target lesions is facilitated by the implanted stents. Thus, in this trial, we decided to perform follow-up angiographies only if the DU was inappropriate or TLR was clinically indicated.
No core labs were utilized for angiography and DU analysis, although the double-blinded, randomized design of this study should avoid any bias. Changes in quality of life with, e.g., standardized questionnaires and possible cost savings by using drug-eluting stents in IPA lesions needs to be clarified in upcoming studies.
Due to the experience in this study the determination of the more accurate toe brachial index in comparison with the ABI must be recommended in IPA studies.
Conclusions
This randomized, double-blind study demonstrates that in the treatment of infrapopliteal lesions SES achieves significantly higher primary and secondary patency rates as compared with BMS. The improvement in RC was significantly better in the SES group than in the BMS group. Considering the selection criteria for patients with CLI excluding RC 6 the amputation rates in this trial were too low to result in significant differences between both cohorts.
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